MI-CP151 was a stage 1b randomised, double-blind, placebo controlled, dose-escalation, multicentre examine To guage multiple intravenous doses of sifalimumab, in adult sufferers with dermatomyositis or polymyositis (NCT00533091). Key demo objectives had been to evaluate the safety and tolerability of sifalimumab in dermatomyositis or polymyositis patients, while one of many exploratory https://chiefg554ugr8.blogars.com/profile